다형성교모세포종 치료의 획기적인 발전으로 생존율과 삶의 질 향상을 향한 길이 열렸습니다.

다형성 교모세포종 치료는 뇌암의 공격적인 특성으로 인해 매우 중요합니다. 교모세포종 종양은 빠르게 성장하고 주변 뇌 조직으로 침윤하는 경향이 있으므로 신속하고 효과적인 중재가 매우 중요합니다. 치료는 증상 완화, 삶의 질 향상, 그리고 생존 기간 연장을 목표로 합니다. 또한, 교모세포종 치료법의 발전은 지속적인 연구에 기여하여 이 복잡한 질병에 대한 더 나은 치료 결과와 더 깊은 이해를 제공할 수 있을 것으로 기대됩니다.

전체 보고서는  https://www.databridgemarketresearch.com/reports/global-glioblastoma-multiforme-treatment-market 에서 확인하세요.

데이터 브리지 마켓 리서치(Data Bridge Market Research)는 2022년부터 2029년까지 예측 기간 동안 글로벌 다형성 교모세포종 치료 시장이 연평균 8.1% 성장할 것으로 분석했습니다. 매우 공격적인 뇌암인 다형성 교모세포종의 발병률 증가가 주요 원인입니다. 인지도 향상, 진단 능력 향상, 그리고 인구통계학적 요인으로 인해 발병 사례가 증가하고 있으며, 이는 치료 옵션 확대를 필요로 합니다.

연구의 주요 결과

기술의 발전이 시장 성장률을 견인할 것으로 예상됩니다.

기술 혁신은 다형성교모세포종 치료 시장의 핵심 동력입니다. 이러한 발전은 더욱 개인화되고 효과적인 치료 전략을 개발하여 환자 개개인의 특성에 맞춰 중재를 조정할 수 있도록 합니다. 특히 정밀 의학은 교모세포종 종양의 분자적 특성을 세밀하게 이해하여 표적 치료법을 선택하는 데 도움을 줍니다. 치료 결과 개선에 대한 기대와 획기적인 혁신의 잠재력은 교모세포종 치료 시장의 연구 개발에 대한 상당한 투자를 유도하여 역동적인 혁신과 발전 환경을 조성합니다.

보고서 범위 및 시장 세분화

세그먼트 분석

글로벌 다형성교모세포종 치료 시장은 유형, 치료, 환자 유형, 약물 유형, 투여 경로, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다.

• 다형성 교모세포종 치료 시장은 유형에 따라 1차 치료(De Novo)와 2차 치료로 구분됩니다. 1차 치료(De Novo)는 89.67%의 시장 점유율로 시장을 장악할 것으로 예상됩니다. 초기 치료는 종양 제거를 극대화하고 추가 성장을 억제하는 것을 목표로 하며, 이는 다형성 교모세포종 치료에 있어 1차 치료 접근법의 중요성을 높이는 데 기여합니다.
• 다형성 교모세포종 치료 시장은 치료 방식에 따라 수술, 방사선 치료, 그리고 약물 치료로 구분됩니다. 수술 분야는 48.95%의 시장 점유율로 시장을 장악할 것으로 예상됩니다. 수술은 종양 부담을 줄이고 방사선 치료 및 약물 치료와 같은 후속 치료를 용이하게 하며, 다형성 교모세포종 관리 효과를 향상시킵니다.

치료 부문의 수술 부문이 2022년부터 2029년까지의 예측 기간 동안 시장을 지배할 것으로 예상됩니다.

The surgery segment of treatment segment is expected to dominate in the glioblastoma multiforme (GBM) treatment market 48.95% market share due to the critical role that surgical intervention plays in the management of this aggressive brain cancer. Glioblastoma multiforme is characterized by its infiltrative nature, making complete surgical resection challenging. However, surgery remains a crucial component of treatment to remove as much of the tumor as possible, alleviating pressure on the surrounding brain tissue and providing a more conducive environment for subsequent therapies.

• On the basis of patient type, the glioblastoma multiforme treatment market is segmented into adult, geriatric and child. The adult segment is expected to dominate the market with 56.97% market share.  It dominates due to the higher incidence of glioblastoma in adults compared to geriatric and pediatric populations. Glioblastoma is more commonly diagnosed in adults, particularly those aged 45-75, contributing to a higher demand for treatment interventions in this age group
• On the basis of drug type, the glioblastoma multiforme treatment market is segmented into generics and branded. The generics segment is expected to dominate the market with a 68.81% market share. The affordability makes generics a preferred choice for patients and healthcare providers, driving their higher market share

The generics segment of drug type segment is expected to dominate the market in the forecast period 2022-2029

The generics segment of drug type segment is expected to dominate in the glioblastoma multiforme (GBM) treatment market 68.81% market share can be attributed to several factors. Generics are essentially identical copies of brand-name drugs that have the same active ingredients, dosage, and efficacy as their branded counterparts. In the case of GBM treatment, where the cost of healthcare is a significant concern, generics offer a more cost-effective alternative without compromising therapeutic benefits.

• On the basis of route of administration, the glioblastoma multiforme treatment market is segmented into parenteral, oral, and others. The parenteral segment is expected to dominate the market with the highest CAGR of 10.2%.  It dominates the due to the fact that parenteral administration allows for direct and rapid delivery of therapeutic agents into the bloodstream, ensuring quicker and more efficient distribution of drugs to the brain, which is crucial in addressing the aggressive nature of glioblastoma multiforme
• On the basis of end user, the glioblastoma multiforme treatment market is segmented into hospitals, clinics, home healthcare, and others. The hospitals segment is expected to dominate the market with a 58.24% market share. The market can be attributed to its comprehensive healthcare infrastructure, advanced diagnostic capabilities, and the ability to provide integrated and specialized care for complex conditions such as glioblastoma multiforme
• On the basis of distribution type, the glioblastoma multiforme treatment market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The hospital pharmacy segment is expected to dominate the market with the highest CAGR of 8.7% in the forecast period of 2022 to 2029 due to the critical nature of the disease, as hospitals are primary centers for comprehensive medical care and specialized treatments

Major Players

Data Bridge Market Research recognizes the following companies as the major global glioblastoma multiforme treatment market players in global glioblastoma multiforme treatment market are F. Hoffmann-La Roche AG (Switzerland), Amgen Inc. (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Varian Medical Systems, Inc. (U.S.), ZEISS International (Germany), Amneal Pharmaceuticals LLC (U.S.), Elekta (Sweden)

Market Developments

• In 2022, Elekta and GE Healthcare announced a groundbreaking collaboration in radiation oncology, positioning themselves as industry leaders poised to transform cancer treatment, including glioblastoma multiforme. This strategic partnership aims to provide hospitals with an integrated solution encompassing imaging and treatment for cancer patients undergoing radiation therapy. The initiative reflects a commitment to advancing capabilities in radiation oncology, with potential implications for the precision and efficiency of glioblastoma multiforme treatment. By tailoring solutions to address the unique needs of each cancer center, Elekta and GE Healthcare contribute to the evolution of patient-centric, multidisciplinary approaches, signifying a milestone in the quest for more sophisticated and effective treatments for aggressive forms of cancer
• In 2022, the Ivy Brain Tumor Center initiated clinical trials for AstraZeneca’s therapy for glioma. The trials specifically target the assessment of safety and efficacy in treating patients with recurrent grade IV glioma. This development reflects a commitment to exploring novel therapeutic options for a challenging condition such as glioma, demonstrating the continual efforts to enhance treatment outcomes and provide hope for patients facing recurrent glioblastoma
• In 2020, AstraZeneca and SciLifeLab Research collaborated to establish a drug biobank dedicated to treating glioblastoma, a subtype of glioma. The initiative involved comparing 1,544 drugs with changes in glioblastoma cells, to repurpose existing drugs and discover new treatments. This innovative approach to leveraging a drug biobank underscores the importance of exploring diverse avenues in the pursuit of effective glioblastoma treatments, potentially paving the way for transformative therapies
• In July 2019, Amgen and Allergan plc announced the availability of MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), in the (U.S.). This launch marked a significant development, potentially impacting the landscape of glioblastoma treatment. The introduction of biosimilars such as MVASI provides additional options and accessibility to treatment, contributing to the overall advancement of therapeutic options in the U.S. for diseases such as glioblastoma

Regional Analysis

Geographically, the countries covered in the global glioblastoma multiforme treatment market report are U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Israel, UAE, Rest of Middle East and Africa

As per Data Bridge Market Research analysis

North America is the dominant region in the global glioblastoma multiforme treatment market during the forecast period 2022-2029

In the North America, the U.S. dominates the glioblastoma multiforme treatment market due to its higher prevalence of glioblastoma multiforme compared to other countries in the region, contributing to increased demand for treatment. Additionally, the U.S. boasts advanced healthcare infrastructure, a robust research ecosystem, and a higher adoption rate of innovative medical technologies, positioning it at the forefront of glioblastoma treatment development and delivery. These factors collectively make the U.S. a key player in driving advancements and dominating the market for glioblastoma multiforme treatments in North America.

Asia-Pacific is estimated to be the fastest-growing region in the global glioblastoma multiforme treatment market for the forecast period 2022-2029

In Asia-Pacific, Japan is expected to experience significant growth during the forecast period in the market due to its investments and advancements in research and development activities. Japan has been at the forefront of medical innovation, with a strong emphasis on cutting-edge technologies and novel treatment approaches. The country's commitment to R&D, coupled with a well-established pharmaceutical and healthcare infrastructure, positions it as a leader in developing and implementing effective treatments for diseases such as glioblastoma multiforme. This leadership role in research and development enhances Japan's capability to drive advancements in glioblastoma treatments, contributing to its anticipated dominance in the Asia-Pacific market.

글로벌 다형성교모세포종 치료 시장 보고서  에 대한 자세한 내용은 여기를 클릭하세요. - https//www.databridgemarketresearch.com/reports/global-glioblastoma-multiforme-treatment-market